Drug-induced end-stage renal disease (ESRD) poses a significant clinical challenge, characterized by the irreversible loss of renal function due to medication toxicity. This review examines strategies for managing and preventing drug-induced ESRD, focusing on pharmacovigilance, risk assessment, and intervention measures. By analyzing the mechanisms of drug-induced nephrotoxicity and identifying high-risk medications, healthcare providers can implement proactive measures to mitigate renal damage. Key strategies include regular monitoring of renal function in patients receiving nephrotoxic medications, dose adjustment based on renal function, and avoidance of potentially harmful drug combinations. Additionally, patient education plays a crucial role in promoting medication adherence and recognizing early signs of renal impairment. Collaborative efforts between healthcare professionals, pharmacists, and patients are essential for minimizing the incidence and severity of drug-induced ESRD. By adopting a multifaceted approach encompassing surveillance, education, and intervention, healthcare systems can effectively safeguard renal health and improve patient outcomes.

Drug-induced end-stage renal disease, nephrotoxicity, pharmacovigilance

Kellum JA, Levin N, Bouman C, Lameire N. Curr Opin Crit Care, 2002; 8:509-514.

Mehta RL, Chertow GM. J Am Soc Nephrol, 2003; 14:2178-2187.

Whelton A. Am J Med, 1999; 106:13S-24S.

Han WK, Bailly V, Abichandani R. Kidney Int, 2002; 62:237- 244.

Baliga R, Ueda N, Walker PD, Shah SV. Drug Metab Rev, 1999; 31:971-997.

Swan SK. Semin Nephrol, 1997; 17:27-33.

Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Semin Nephrol, 1997; 17:15-26.

Solomon R.. Kidney Int, 1998; 53:230-242.

Murphy SW, Barrett BJ, Parfrey PS. J Am Soc Nephrol, 2000; 11:177-182.

Waybill MM, Waybill PN. JV asc Intervent Radiol, 2001; 12:3-9.

Kintzel PE. Drug Saf, 2001; 24:19-38.